Navigation Links
Aoxing Pharmaceutical Company Announces $3.2 Million Financing
Date:12/7/2011

JERSEY CITY, N.J., Dec. 7, 2011 /PRNewswire/ -- Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has signed a three-way financing agreement with Shijiazhuang Construction Investment Group Co., Ltd and China Construction Bank.

Shijiazhuang Construction Investment Group, a city-government owned investment firm, has commissioned China Construction Bank to disburse a working capital term loan of RMB 20 mil (approximately $3.2 mil) to Hebei Aoxing Pharmaceutical Group.  The loan matures in one year and carries an annual interest rate of 15%.  

Zhenjiang Yue, Aoxing's Chairman and CEO, commented, "The loan reflects the regional government's support for local enterprise as well as confidence in the future prospects for Aoxing Pharma."

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnerships with QRxPharma, and Phoenix PharmaLabs, Inc.  For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.

Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. The Company may also make written or oral forward-looking statements in its periodic reports filed with the U.S. Securities and Exchange Commission and other written materials and in oral statements made by its officers, directors or employees to third parties. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by these forward-looking statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2011, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

CONTACT:  

Aoxing Pharmaceutical Company:
Bob Ai
Chief Financial Officer
646-367-1767
investor.relations@aoxingpharma.com

Investor Relations:
The Trout Group
Brian Korb
646-378-2923
bkorb@troutgroup.com


'/>"/>
SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China
2. Aoxing Pharmaceutical Company Has No Comment on Unusual Trading Activity
3. Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
4. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
5. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
6. K-V Pharmaceutical Company Comments on Recent Settlement With the Department of Justice
7. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
8. Onyx Pharmaceuticals to Host a Teleconference to Reprise Key Data From the American Society of Hematology Meeting
9. Bayer HealthCare LLC Stops Trademark Infringement by Indian Pharmaceutical Company
10. Unity Management Group, Inc. Receives Contract From Sun Pharmaceutical Indias Largest Pharmaceutical Companies for $105,000
11. Global Pharmaceutical Services Company Turns to Glowpoints OpenVideo™ Cloud
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
(Date:5/4/2016)... Israel , May 4, 2016 ... that BiondVax,s CEO, Dr. Ron Babecoff , will be ... New York City . On Thursday, May ... 2016, a conference presented by Joseph Gunner & ... The BiondVax presentation that Dr. Babecoff will be using ...
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... An essential tool for ... and certain Canadian provinces is now available from the International Association of Industrial ... , The report, Workers’ Compensation Laws as of January 1, 2016, ...
(Date:5/5/2016)... ... 05, 2016 , ... Tim Dieter has announced the latest ... Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center on behalf of ... Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . , Veteran’s Freedom ...
(Date:5/5/2016)... ... ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC in Atlanta, Georgia proudly ... certified and the only facial plastic surgeon in Atlanta to offer Micro-droplet Fat ... stem cells can be used to provide stabilization to hair transplant results or they ...
(Date:5/5/2016)... York) , ... (PRWEB) May 05, 2016 , ... ... talent acquisition startup, HireNurses, on the eve of National Nurses Week (May ... nurses and healthcare employers. With their enrollment into the Talent Tech Lab Virtual Incubation ...
(Date:5/5/2016)... Rochester, NY (PRWEB) , ... May 05, 2016 ... ... app is now available for iOS and Android devices. VisualDx is the ... expanded to include diagnostic support across general medicine. The system speeds diagnosis, ...
Breaking Medicine News(10 mins):